Skip to main content
SpringerLink
Log in

Hypertension in 2015

Resistant hypertension: impact and evolving treatment options

  • Year in Review
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Combination therapy with optimal doses of multiple antihypertensive drugs fails to achieve blood pressure (BP) control in up to 15% of hypertensive patients. Key studies in 2015 highlighted the risks of uncontrolled hypertension and evaluated new therapeutic modalities designed to achieve satisfactory BP control in patients with treatment-resistant hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Oparil, S. & Schmieder, R. E. New approaches in the treatment of hypertension. Circ. Res. 116, 1074–1095 (2015).

    Article  CAS  Google Scholar 

  2. Sim, J. J. et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 88, 622–632 (2015).

    Article  Google Scholar 

  3. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).

    Article  Google Scholar 

  4. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).

  5. Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).

    Article  CAS  Google Scholar 

  6. Bohm, M. et al. Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 65, 766–774 (2015).

    Article  Google Scholar 

  7. Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059–2068 (2015).

    Article  CAS  Google Scholar 

  8. Beaussier, H. et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J. Hypertens. 33, 2526–2533 (2015).

    Article  CAS  Google Scholar 

  9. Bobrie, G. et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J. Hypertens. 30, 1656–1664 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors' work is partly supported by NIH grants DK100081, DK73608, HL123160, and DK102325.

Author information

Authors and Affiliations

  1. Division of Nephrology & Hypertension, Mayo Clinic, 200 First Street SW, Rochester, 55905, Minnesota, USA

    Lilach O. Lerman & Stephen C. Textor

Authors
  1. Lilach O. Lerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen C. Textor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lilach O. Lerman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lerman, L., Textor, S. Resistant hypertension: impact and evolving treatment options. Nat Rev Nephrol 12, 70–72 (2016). https://doi.org/10.1038/nrneph.2015.199

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.199

  • Springer Nature Limited

This article is cited by

Search

Navigation